Our pipeline
Building the evidence to expand possibilities.
We are initially focused on MSS colorectal cancer and pancreatic ductal adenocarcinoma, two tumor types with significant unmet need. Our goal is to generate the preclinical evidence needed to evaluate the platform and inform future development decisions.
Initial indications
Parallel research tracks
Platform layers
Provisional patent applications
Two indications, studied in parallel.
Two independent research tracks in immune-cold cancers with significant unmet need. Here is why each one matters.
Indication 01 · Track A
MSS colorectal cancer
A large patient population with limited treatment options in the metastatic setting. Microsatellite-stable disease is typically immune-cold, so today’s checkpoint inhibitors rarely work.
Checkpoint blockade works only when tumors are visible
Objective response to PD-1 blockade in colorectal cancer, by tumor type
MSS tumors are about 95% of metastatic cases, and the group LurexBio is designed to reach.
| Group | Value |
|---|---|
| MSI-high (dMMR) | 62% |
| MSS (pMMR) | 0% |
Sources: American Cancer Society, 2026 · Clin Adv Hematol Oncol, 2022 · Le et al., ASCO 2015 update of NEJM study
Indication 02 · Track B
Pancreatic cancer (PDAC)
An aggressive disease with high unmet need and poor outcomes, and one of the most immune-cold tumor types.
Survival depends on finding it early, and most cases are found late
Five-year relative survival by stage at diagnosis
| Group | Value |
|---|---|
| Localized | 44% |
| Regional | 17% |
| Distant | 3% |
| All stages | 13% |
Sources: ACS Cancer Statistics 2026, via PanCAN · Lustgarten Foundation, 2026 · American Cancer Society, pancreatic survival rates
Across both tracks
Two research questions, tested in parallel.
Can the recognition signal be installed at the tumor cell surface?
We are testing whether the Atraxis™ delivery platform can reliably present NeoTag™ signals across both tracks.
Does the immune system detect and respond to it?
We are testing whether immune cells engage once a signal is installed at the tumor site.
Disease figures are drawn from the published sources linked above. They describe the disease landscape and are not LurexBio results.
From discovery to potential impact.
Our progress to date, and the path ahead. Completed milestones are dated. Future stages follow a sequence, not a schedule: each begins only upon the success of the previous one.
- 2025Founded
LurexBio is founded
Founded in Fort Lauderdale, Florida, building on founder James Clark’s years of research into why the immune system fails to recognize certain solid tumors.
- Nov 2025Intellectual property
First patent filings announced
Multiple U.S. provisional patent applications filed covering our immune-signal and vesicle-based targeting systems, a first step toward international protection.
Source: Business Wire, Nov 6, 2025
- 2026Leadership
Leadership team formalized
A leadership team formed to drive translational rigor and development strategy.
- 2026Scientific advisors
Scientific Advisory Board expands
Our advisors bring more than 200 years of collective oncology and immunology experience.
- 2026Platform & IP
Four-layer platform defined
NeoTag™, Atraxis™, AegisCore™ and StratIQ™ defined as one programmable system, with 27 provisional patent applications filed to date.
- NowCurrent stage
Preclinical research: install and recognize
Two research questions tested in parallel across MSS CRC and PDAC: can the signal be installed at the tumor surface, and does the immune system respond to it?
- Next stageTranslational validation
Expand and confirm
Expanding signals and models across both indications to strengthen the evidence base.
- Future objectiveIND-enabling development
Prepare for the clinic
Studies to support a future regulatory filing, pending supporting data and resources.
- Future objectiveClinical development
Advance through partnership
A future objective, pending regulatory clearance and additional data. Indication-specific partnerships may support this stage.
These stages represent research questions and development objectives, not predicted outcomes. Timelines may change based on scientific findings, intellectual property strategy, and collaboration schedules.
Join us in advancing a new approach.
We welcome conversations with investors, potential partners, and talented individuals who share our vision.